Cofco Historical Income Statement

000930 Stock

5.85 0.07 1.18%

Historical analysis of Cofco Biochemical income statement accounts such as Selling General Administrative of 184.1 M, Total Revenue of 21.4 B or Operating Income of 115.9 M can show how well Cofco Biochemical Anhui performed in making a profits. Evaluating Cofco Biochemical income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Cofco Biochemical's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Cofco Biochemical Anhui latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cofco Biochemical Anhui is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cofco Biochemical Anhui. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

About Cofco Income Statement Analysis

Cofco Biochemical Anhui Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Cofco Biochemical shareholders. The income statement also shows Cofco investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Cofco Biochemical Income Statement Chart

At present, Cofco Biochemical's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Total Revenue is expected to grow to about 21.4 B, whereas Selling General Administrative is forecasted to decline to about 184.1 M.

Total Revenue Income Tax Expense Total Operating Expenses

Total Revenue

Total revenue comprises all receipts Cofco Biochemical Anhui generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Cofco Biochemical's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Cofco Biochemical Anhui current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cofco Biochemical Anhui. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

	2021	2022	2023	2024 (projected)
EBITDA	2.0B	1.9B	2.2B	1.5B
Interest Income	15.4M	16.2M	16.2M	10.9M

Ebitda Interest Income

Cofco Biochemical income statement Correlations

	Selling General Administrative	Total Revenue	Operating Income	Cost Of Revenue	Income Before Tax	Net Income	Income Tax Expense	Minority Interest	Research Development	Gross Profit	Other Operating Expenses	Net Income From Continuing Ops	Ebit	Total Operating Expenses	Total Other Income Expense Net	Tax Provision	Net Interest Income	Interest Income	Ebitda	Reconciled Depreciation
Selling General Administrative		0.2	0.34	0.14	0.21	0.22	-0.27	0.58	-0.1	0.42	-0.23	0.23	-0.11	0.16	0.07	0.0	-0.47	-0.16	-0.01	0.32
Total Revenue	0.2		0.72	1.0	0.39	0.33	0.79	0.09	0.58	0.87	0.3	0.7	0.83	0.96	0.58	0.84	0.52	0.86	0.92	0.91
Operating Income	0.34	0.72		0.66	0.87	0.85	0.4	0.26	0.27	0.85	0.25	0.85	0.57	0.75	0.53	0.84	0.31	0.62	0.65	0.69
Cost Of Revenue	0.14	1.0	0.66		0.33	0.27	0.82	0.05	0.61	0.84	0.31	0.66	0.84	0.96	0.56	0.83	0.55	0.87	0.93	0.9
Income Before Tax	0.21	0.39	0.87	0.33		1.0	0.19	0.13	0.03	0.55	0.16	0.66	0.3	0.41	0.35	0.62	0.18	0.35	0.34	0.34
Net Income	0.22	0.33	0.85	0.27	1.0		0.13	0.16	-0.03	0.52	0.16	0.64	0.26	0.36	0.34	0.56	0.13	0.29	0.28	0.29
Income Tax Expense	-0.27	0.79	0.4	0.82	0.19	0.13		-0.25	0.57	0.55	0.55	0.46	0.86	0.75	0.53	0.7	0.76	0.83	0.85	0.69
Minority Interest	0.58	0.09	0.26	0.05	0.13	0.16	-0.25		-0.38	0.38	0.22	0.4	0.06	0.07	0.43	-0.05	-0.02	-0.27	-0.12	0.21
Research Development	-0.1	0.58	0.27	0.61	0.03	-0.03	0.57	-0.38		0.25	-0.09	0.01	0.29	0.68	-0.17	0.5	0.36	0.72	0.7	0.55
Gross Profit	0.42	0.87	0.85	0.84	0.55	0.52	0.55	0.38	0.25		0.31	0.89	0.79	0.85	0.74	0.81	0.36	0.65	0.77	0.9
Other Operating Expenses	-0.23	0.3	0.25	0.31	0.16	0.16	0.55	0.22	-0.09	0.31		0.49	0.64	0.26	0.7	0.29	0.61	0.29	0.35	0.22
Net Income From Continuing Ops	0.23	0.7	0.85	0.66	0.66	0.64	0.46	0.4	0.01	0.89	0.49		0.78	0.69	0.86	0.78	0.46	0.58	0.64	0.67
Ebit	-0.11	0.83	0.57	0.84	0.3	0.26	0.86	0.06	0.29	0.79	0.64	0.78		0.79	0.86	0.75	0.68	0.78	0.86	0.78
Total Operating Expenses	0.16	0.96	0.75	0.96	0.41	0.36	0.75	0.07	0.68	0.85	0.26	0.69	0.79		0.52	0.85	0.5	0.9	0.95	0.92
Total Other Income Expense Net	0.07	0.58	0.53	0.56	0.35	0.34	0.53	0.43	-0.17	0.74	0.7	0.86	0.86	0.52		0.52	0.54	0.45	0.55	0.58
Tax Provision	0.0	0.84	0.84	0.83	0.62	0.56	0.7	-0.05	0.5	0.81	0.29	0.78	0.75	0.85	0.52		0.61	0.85	0.83	0.75
Net Interest Income	-0.47	0.52	0.31	0.55	0.18	0.13	0.76	-0.02	0.36	0.36	0.61	0.46	0.68	0.5	0.54	0.61		0.64	0.58	0.42
Interest Income	-0.16	0.86	0.62	0.87	0.35	0.29	0.83	-0.27	0.72	0.65	0.29	0.58	0.78	0.9	0.45	0.85	0.64		0.95	0.73
Ebitda	-0.01	0.92	0.65	0.93	0.34	0.28	0.85	-0.12	0.7	0.77	0.35	0.64	0.86	0.95	0.55	0.83	0.58	0.95		0.89
Reconciled Depreciation	0.32	0.91	0.69	0.9	0.34	0.29	0.69	0.21	0.55	0.9	0.22	0.67	0.78	0.92	0.58	0.75	0.42	0.73	0.89

Click cells to compare fundamentals

Cofco Biochemical Account Relationship Matchups

Cofco Biochemical income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Interest Expense	162.1M	94.3M	157.8M	87.1M	112.8M	118.4M
Selling General Administrative	1.3B	346.2M	374.3M	345.2M	193.7M	184.1M
Total Revenue	19.5B	19.9B	23.5B	19.9B	20.4B	21.4B
Operating Income	1.5B	1.2B	1.9B	1.7B	122.0M	115.9M
Cost Of Revenue	16.7B	17.8B	20.8B	17.7B	19.3B	20.2B
Income Before Tax	666.3M	801.9M	1.4B	1.4B	(542.5M)	(515.4M)
Net Income Applicable To Common Shares	592.8M	593.1M	1.1B	1.1B	1.2B	1.3B
Net Income	592.8M	593.1M	1.1B	1.1B	(601.6M)	(571.5M)
Income Tax Expense	107.5M	173.8M	247.9M	301.0M	346.2M	363.5M
Minority Interest	375.5M	408.1M	165.2K	(2.1M)	14.7M	13.9M
Research Development	87.2M	113.7M	119.3M	132.9M	165.3M	105.0M
Gross Profit	2.7B	2.1B	2.6B	2.3B	1.1B	1.8B
Other Operating Expenses	76.5M	125.5M	109.0M	181.4M	208.6M	158.9M
Net Income From Continuing Ops	558.9M	628.2M	1.1B	1.1B	(616.3M)	(585.5M)
Ebit	593.4M	799.2M	1.7B	1.5B	1.8B	1.8B
Total Operating Expenses	17.9B	18.7B	21.6B	18.2B	20.3B	16.1B
Tax Provision	107.5M	173.8M	250.1M	298.9M	73.8M	139.8M
Net Interest Income	(157.0M)	(90.0M)	(145.7M)	(74.5M)	(101.7M)	(106.8M)
Interest Income	9.9M	10.6M	15.4M	16.2M	16.2M	10.9M
Ebitda	1.3B	1.3B	2.0B	1.9B	2.2B	1.5B
Reconciled Depreciation	425.3M	436.4M	446.3M	458.2M	491.8M	479.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Other Information on Investing in Cofco Stock

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cofco Historical Income Statement

About Cofco Income Statement Analysis

Cofco Biochemical Income Statement Chart

Total Revenue

Total Operating Expenses

Cofco Biochemical income statement Correlations

Cofco Biochemical Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cofco Biochemical income statement Accounts

Also Currently Popular

Other Information on Investing in Cofco Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cost Of Revenue	+ 1.0	Total Revenue
Net Income	+ 1.0	Income Before Tax
Total Operating Expenses	+ 0.96	Total Revenue
Total Operating Expenses	+ 0.96	Cost Of Revenue
Ebitda	+ 0.95	Total Operating Expenses
Ebitda	+ 0.95	Interest Income

Net Interest Income	- 0.47	Selling General Administrative
Research Development	- 0.38	Minority Interest
Interest Income	- 0.27	Minority Interest
Income Tax Expense	- 0.27	Selling General Administrative
Minority Interest	- 0.25	Income Tax Expense
Other Operating Expenses	- 0.23	Selling General Administrative